Wells Fargo downgraded Incyte (INCY) to Equal Weight from Overweight with a price target of $107, down from $116. The firm says its upgrade thesis has largely played out. Given few material catalysts in the near-term, the stock is likely to be range bound from here, the analyst tells investors in a research note.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INCY:
- Incyte downgraded to Equal Weight from Overweight at Wells Fargo
- Incyte Advances Microneedle Skin Sampling Platform With Completion of Observational Study in Atopic Dermatitis
- Incyte: Transitioning Beyond Jakafi With a Promising but Unproven Late-Stage Pipeline Warrants Hold Rating
- Incyte: Post-Jakafi Revenue Gap and Execution Risks Undermine Confidence, Justifying Sell Rating
- Incyte price target raised to $128 from $101 at TD Cowen